Roche's Breast Cancer Drug Perjeta Receives Green Light From EU
 

Today, Roche declared that the European Union gave a positive recommendation for the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel in patients with HER2-positive metastatic or location specific recurrent breast cancer that cannot be removed with surgery...

More...